CE Broker Appoints Industry Veteran John Barnes as Chief Product & Technology Officer
JACKSONVILLE, Fla., March 15, 2023 (Newswire.com)
–
CE Broker, the leader in healthcare compliance and continuing education (“CE”) management software, announ…
Diverge Health Launched to Build Upon a Decade of Experience Serving Underserved Patients in New York
City Health Works’ success in New York drives national movement to support providers serving low-income patients.
Diverge Health
Diverge Health Logo
BOSTON, March 15, 2023 (Newswire.com)
–
Today, Binoy Bhansali, Manmeet Kaur and Anne Robinson announced the formation of Diverge Health – a new value-based care company that comprehensively supports primary care providers to better serve patients on Medicaid.
The company is building off the success of New York-based City Health Works, founded by Kaur in 2012 to partner with primary care practices and deploy local community health worker-led, technology-enabled health coaching services to high-needs patients. Patients enrolled in the program saw a greater than 45 percent reduction in year-over-year cost of care, a 50 percent reduction in emergency room visits, and significant clinical improvements overall while boasting a net promoter score of 90.
“Having spent the last decade proving that City Health Works’ model delivers extraordinary results for patients, our workforce and clinic partners, it is a privilege to join Diverge Health and build upon this success,” said Manmeet Kaur, co-founder and chief population health officer at Diverge Health. “I’m excited to partner with a deeply experienced set of colleagues to meaningfully scale and adapt City Health Works’ solution across the nation.”
In 2023, Diverge Health acquired the intellectual property of City Health Works. The company will take lessons learned from City Health Works and deploy its model as a component of a broader offering to primary care providers in multiple markets this year.
“Healthcare providers that support the most vulnerable populations in our country require a different model to be able to holistically address patients’ needs,” said Anne Robinson, chief people and network development officer at Diverge Health. “I am thrilled to be able to leverage my past experiences in risk-based primary care to be a part of an organization that affords these providers the resources required to best engage patients in their health journeys.”
Robinson joins Diverge Health from VillageMD, where she most recently served as executive vice president of growth and led a team that delivered a 400 percent increase of VillageMD’s provider network in one year. Anne also spent five years as VillageMD’s chief people officer, where she expanded an early, founding team to more than 6,500 employees during her tenure.
“We are grateful to have an opportunity to build an impactful organization that serves practices and patients across the country,” said Binoy Bhansali, co-founder and chief executive officer of Diverge Health. “Primary care providers serving low-income patients have the toughest of jobs. They are doing their best to care for a high-needs population without adequate infrastructure to fully support patients’ needs. Many don’t have the financial wherewithal to take on value-based contracts with health plans. Diverge Health was built to serve these practices. We equip them with highly trained community health teams, clinical solutions and data to produce better outcomes for their patients.”
Prior to founding Diverge Health, Bhansali headed diversification efforts at SCAN, a $4+ billion nonprofit healthcare organization serving older adults across the country. In partnership with the company’s leadership and corporate development teams, he helped spearhead SCAN’s combination with CareOregon alongside entry into the Program of All-Inclusive Care for the Elderly (PACE), in-home primary care, in-home chronic disease management and street medicine for individuals experiencing homelessness. Bhansali also served as a partner at venture capital firm Sandbox Industries, where he invested in healthcare services companies focused on serving low-income patient populations.
Diverge Health is backed by well-known healthcare venture funds, including Triple Aim Partners and GV (Google Ventures).
About Diverge
Founded in 2022, Diverge Health supports primary care providers to extend their reach and better serve vulnerable patients. For more information, visit divergecares.com.
About Triple Aim Partners
Triple Aim Partners builds healthcare companies that improve the quality, experience and total cost of healthcare in partnership with outstanding entrepreneurs. Since 2019, the organization has co-founded and launched seven impactful companies. Visit tripleaim.com to learn more.
-XXX-
Contact Information:
Regina Vaccari
Owner/Principal, Vaccari Communications
(702) 337-1781
Original Source:
Diverge Health Launched to Build Upon a Decade of Experience Serving Underserved Patients in New York
Gibson Oncology Expands Its Board of Directors With Accomplished Leadership in Oncology Clinical Development and Corporate Strategy
MIAMI, March 14, 2023 (Newswire.com)
–
Gibson Oncology, a privately held Oncology preclinical and clinical development company advancing novel, targeted…
Compass Health Center to Launch Enhanced Summer Creative Arts Intensive Outpatient Program
Creative Arts Therapies Help Children & Teens Improve Mental Health Post-Covid Pandemic
Summer Creative Arts Program
…
CodaPet Expands Compassionate In-Home Pet Euthanasia Services to Nashville, TN, and Surrounding Cities
The Fresno-based startup enables a network of licensed veterinarians to provide peaceful in-home euthanasia to ease the passing of pets at home, surrounded by loved ones.
…
Independent Research Shows How Interoperability Platforms and Partners Unlock True Innovation
By embracing data automation via open standards, providers can lift technical barriers that impede workflow efficiencies.
…
Carebox Launches Application That Connects Patients to Clinical Trials
Carebox Connect™ empowers patients, families, and their physicians to find treatment options only available in clinical trials.
Carebox Healthcare …
Florence Healthcare Now Equipping IQVIA Research Sites With Site Enablement Technology
New multiyear collaboration between Florence Healthcare and IQVIA to ensure research sites participating in IQVIA studies have access to best-in-class site enablement technology to streamline operations and power remot…
Pirche Joins C-Path’s Transplant Therapeutics Consortium (TTC)
BERLIN, March 13, 2023 (Newswire.com)
–
The Critical Path Institute (C-Path), an independent nonprofit, public-private partnership with the U.S. Food and Drug Administration (FDA) and Pirche AG, the global leader in AI-powered molecular matching and prediction analysis, announced a new collaboration that will see Pirche become the latest member of C-Path’s Transplant Therapeutics Consortium (TTC).
“TTC is excited to welcome Pirche to join our ongoing efforts to bring together the bio-pharmaceutical industry, diagnostic companies, academia, professional societies, and government and regulatory agencies, to accelerate innovation and application of new tools across pharmaceuticals, devices, and diagnostics for transplant patients.” said Amanda Klein, Executive Director of TTC.
Co-founded by the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS), TTC represents an ongoing partnership between key stakeholders dedicated to advancing the regulatory science needs in transplantation. The iBOX, a composite biomarker panel developed to predict the probability of long-term kidney graft survival, represents one such advancement. The consortium’s primary initiative includes the qualification of the iBOX as a reasonably likely surrogate endpoint with FDA in order to address the unmet needs of kidney transplantation and bring innovative therapies to patients in a timely, efficient manner.
Regarding the new collaboration, Pirche CEO, Thomas Klein said, “We are thrilled to be a part of the TTC and to support the consortium in delivering for transplant specialists and patients. TTC offers an opportunity to collaborate with the transplant community and maximize learnings across the field.”
Dr. Klemens Budde, Pirche scientific advisor, TTC Member, and head of Transplant Nephrology at the Charité University Hospital in Berlin added, “Pirche and the PIRCHE epitope matching technology compliment the TTC’s objectives perfectly. Epitope matching improves immunologic risk assessment towards a personalized treatment and may further complement initiatives like iBOX for kidney transplantation.”
About C-Path
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. Visit c-path.org.
C-Path is supported by the U.S. FDA/HHS . The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
About TTC
The Transplant Therapeutics Consortium (TTC) was launched in April 2017. It aims to accelerate the medical product development process for transplantation by identifying 1) areas that hinder product development, 2) potential biomarkers, endpoints, quantitative tools, or process improvements as solutions to address those areas, and 3) appropriate pathways to regulatory endorsement for developed solutions.
About Pirche AG
Pirche AG, headquartered in Berlin, Germany is a leading artificial intelligence company focused on establishing digital solutions in molecular medicine. We aim to provide clinical decision support for predictive medicine through AI-powered algorithms. With better matching we help clinicians to individualize care to bring a better quality of life to transplant patients. To learn more visit www.pirche.com.
Contact Information:
Bethany Dale
Vice President – Global Commercialization, Pirche AG
(+1) 954 816 5707
Original Source:
Pirche Joins C-Path’s Transplant Therapeutics Consortium (TTC)
Coastal Vision Medical Group is the First in Orange County and the Inland Empire to Offer Custom Laser Cataract Surgery With the ALLY® Adaptive Cataract Treatment System
Dr. Dan B. Tran, Founder and Medical Director at Coastal Vision Medical Group, is the first surgeon in Southern California’s Orange County and Inland Empire regions to offer custom laser cataract surgery using the ALLY® Adaptive Cataract Treatment System.
Coastal Vision \/ ALLY Logo
Logo for Coastal Vision Medical Group and the logo for the ALLY Surgical System displayed next to each other with a vertical line separating them as a divider.
ORANGE, Calif., March 10, 2023 (Newswire.com)
–
Coastal Vision Medical Group will be among the first practices in Southern California and the first in the Orange County region to offer cataract surgery with the ALLY® Adaptive Cataract Treatment System to patients.
ALLY is the first platform to combine advanced imaging and optimized femtosecond laser technologies into one compact system for cataract surgery. ALLY is designed to complete the entire cataract surgery procedure in a single, sterile setting, reducing the overall time and improving the experience for the patient and surgeon. In addition to improved efficiencies, ALLY’s proprietary features are enabling surgeons to deliver improved visual outcomes. ALLY takes laser cataract surgery to a whole new level.
“We are proud to be the first premier eye care center in Orange County and the Inland Empire to offer cataract surgery with ALLY® Adaptive Cataract Treatment System to our patients. ALLY provides a premium experience, reducing overall surgery time, and enables our team to consistently achieve optimum visual outcomes,” said Dr. Dan B. Tran, Founder and Medical Director of Coastal Vision. “I have worked closely with the LENSAR development team and believe that ALLY will change the way surgeons approach cataract surgery. We now have a platform that elevates the patient experience and surgical outcomes.”
The Coastal Vision Medical Group is committed to providing patients with the most advanced eye surgeries available. By partnering with manufacturers, such as LENSAR, Coastal Vision Medical Group is at the forefront of eye care by utilizing state-of-the-art technologies and providing premium patient care.
To learn more about the benefits of the ALLY® Adaptive Cataract Treatment System visit: www.coastal-vision.com
About Coastal Vision Medial Group
Coastal Vision Medical Group is a physician owned, premier eye care provider, established in 1999 with multiple locations servicing Orange County, Los Angeles Metropolitan Area, and the Inland Empire. We have four eye care centers with locations in Chino, Irvine, Long Beach, and Orange. Our surgeons are highly trained and experienced in LASIK, Cataract Surgery, the treatment of Glaucoma, and other general ophthalmology conditions. Coastal Vision surgeons and optometrists actively participate in FDA Ophthalmic Clinical Studies to further expand future medical and surgical offerings. These options can often be made available earlier to our patients as part of clinical trials.
Our mission is to provide the best possible medical and surgical Ophthalmological Care to our patients utilizing the latest and best technology available.
Contact Information:
Gina Valdemar
Director, Marketing & Business Development
(888) 501-4496